209 related articles for article (PubMed ID: 9366345)
1. Cryosurgical ablation of prostate cancer: patterns of cancer recurrence.
Shinohara K; Rhee B; Presti JC; Carroll PR
J Urol; 1997 Dec; 158(6):2206-9; discussion 2209-10. PubMed ID: 9366345
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of cryosurgical ablation of prostate cancer: the University of California, San Francisco experience.
Koppie TM; Shinohara K; Grossfeld GD; Presti JC; Carroll PR
J Urol; 1999 Aug; 162(2):427-32. PubMed ID: 10411051
[TBL] [Abstract][Full Text] [Related]
3. Salvage radiotherapy for prostate cancer recurrence after cryosurgical ablation.
Burton S; Brown DM; Colonias A; Cohen J; Miller R; Rooker G; Benoit R; Merlotti L; Quinn A; Kalnicki S
Urology; 2000 Nov; 56(5):833-8. PubMed ID: 11068312
[TBL] [Abstract][Full Text] [Related]
4. Cryosurgical ablation of the prostate: two-year prostate-specific antigen and biopsy results.
Cohen JK; Miller RJ; Rooker GM; Shuman BA
Urology; 1996 Mar; 47(3):395-401. PubMed ID: 8633408
[TBL] [Abstract][Full Text] [Related]
5. Cryoablation for clinically localized prostate cancer using an argon-based system: complication rates and biochemical recurrence.
De La Taille A; Benson MC; Bagiella E; Burchardt M; Shabsigh A; Olsson CA; Katz AE
BJU Int; 2000 Feb; 85(3):281-6. PubMed ID: 10671882
[TBL] [Abstract][Full Text] [Related]
6. The relationship between biochemical failure and time to nadir in patients treated with external beam therapy for T1-T3 prostate carcinoma.
Aref I; Eapen L; Agboola O; Cross P
Radiother Oncol; 1998 Aug; 48(2):203-7. PubMed ID: 9783893
[TBL] [Abstract][Full Text] [Related]
7. Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure.
Ray ME; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Zelefsky MJ; Zietman AL; Kuban DA
Urology; 2006 Dec; 68(6):1257-62. PubMed ID: 17141830
[TBL] [Abstract][Full Text] [Related]
8. Cryosurgical treatment of localized prostate cancer (stages T1 to T4): preliminary results.
Shinohara K; Connolly JA; Presti JC; Carroll PR
J Urol; 1996 Jul; 156(1):115-20; discussion 120-1. PubMed ID: 8648771
[TBL] [Abstract][Full Text] [Related]
9. Focal cryosurgical ablation of the prostate: a single institute's perspective.
Hale Z; Miyake M; Palacios DA; Rosser CJ
BMC Urol; 2013 Jan; 13():2. PubMed ID: 23311921
[TBL] [Abstract][Full Text] [Related]
10. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival.
Lee WR; Hanlon AL; Hanks GE
J Urol; 1996 Aug; 156(2 Pt 1):450-3. PubMed ID: 8683700
[TBL] [Abstract][Full Text] [Related]
11. Radiotherapy for localized prostate carcinoma. The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen.
Crook JM; Bahadur YA; Bociek RG; Perry GA; Robertson SJ; Esche BA
Cancer; 1997 Jan; 79(2):328-36. PubMed ID: 9010106
[TBL] [Abstract][Full Text] [Related]
12. Single center experience with third-generation cryosurgery for management of organ-confined prostate cancer: critical evaluation of short-term outcomes, complications, and patient quality of life.
Hubosky SG; Fabrizio MD; Schellhammer PF; Barone BB; Tepera CM; Given RW
J Endourol; 2007 Dec; 21(12):1521-31. PubMed ID: 18186694
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of prostate specific antigen nadir after salvage cryotherapy.
Greene GF; Pisters LL; Scott SM; Von Eschenbach AC
J Urol; 1998 Jul; 160(1):86-90. PubMed ID: 9628611
[TBL] [Abstract][Full Text] [Related]
14. Percutaneous, transperineal cryosurgery of the prostate as salvage therapy for post radiation recurrence of adenocarcinoma.
Miller RJ; Cohen JK; Shuman B; Merlotti LA
Cancer; 1996 Apr; 77(8):1510-4. PubMed ID: 8608536
[TBL] [Abstract][Full Text] [Related]
15. Predictors of prostate-specific antigen biochemical recurrence in patients undergoing primary whole-gland prostate cryoablation.
Liu YY; Chiang PH; Chuang YC; Lee WC; Cheng YT; Wang HJ
Ann Surg Oncol; 2015 May; 22(5):1612-7. PubMed ID: 25287436
[TBL] [Abstract][Full Text] [Related]
16. Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome.
Zietman AL; Coen JJ; Shipley WU; Willett CG; Efird JT
J Urol; 1994 Mar; 151(3):640-5. PubMed ID: 7508522
[TBL] [Abstract][Full Text] [Related]
17. Postneoadjuvant hormone PSA levels and prognosis in locally advanced prostate cancer.
Velasco J; Tekyi-Mensah S; Bolton S; Forman JD
Urology; 1999 Aug; 54(2):325-8. PubMed ID: 10443733
[TBL] [Abstract][Full Text] [Related]
18. [Role of transrectal ultrasonography in the follow-up of patients treated with prostatic cryosurgery].
Galosi AB; Muzzonigro G; Polito M; Minardi D; Dellabella M; Lugnani F; Polito M
Arch Ital Urol Androl; 2000 Dec; 72(4):276-81. PubMed ID: 11221054
[TBL] [Abstract][Full Text] [Related]
19. [The correlation of PSA-nadir PS recurrence after total HIFU-ablation in patients with localized prostate cancer].
Fomkin RN; Krupinov GE; Churakov AA; Shatylko TV; Fomkina OA; Zhmakin VA
Urologiia; 2020 Sep; (4):79-83. PubMed ID: 32897659
[TBL] [Abstract][Full Text] [Related]
20. Preliminary outcomes following cryosurgical ablation of the prostate in patients with clinically localized prostate carcinoma.
Long JP; Fallick ML; LaRock DR; Rand W
J Urol; 1998 Feb; 159(2):477-84. PubMed ID: 9649266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
